{
    "code": "60001063",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001063",
    "time": "2023-07-27 23:42:03",
    "許可證字號": "衛部菌疫輸字第001063號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "116\/12\/07",
    "發證\/登錄日期": "106\/12\/07",
    "許可證\/登錄種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000106308",
    "中文品名": "達癬治&#174; 注射劑",
    "英文品名": "TALTZ&#174; injection",
    "適應症": "1.\t斑塊性乾癬：適用於治療適合接受全身性治療的中至重度斑塊性乾癬之6 歲以上兒童及成人病人。\r\n2.\t乾癬性關節炎：適用於治療患有活動性乾癬性關節炎之成人病人。\r\n3.\t僵直性脊椎炎：適用於治療活動性僵直性脊椎炎之成人病人。\r\n4.     無放射影像確認之中軸性脊椎關節炎(Non-radiographic axial \r\n       spondyloarthritis，簡稱nr-axSpA) : 用於治療嚴重活動性無放射影像確認\r\n       之中軸性脊椎關節炎且符合下列所有條件的成人病人：\r\n       (1) 對非類固醇抗發炎藥物(NSAID)治療反應不佳或無法耐受。\r\n       (2) 其C反應蛋白(C-reactive protein，簡稱CRP)濃度升高。\r\n       (3) 核磁共振造影(MRI)檢查證據顯示有發炎的客觀跡象。\r\n       (4) HLA-B27陽性。",
    "劑型": "270注射劑",
    "包裝": "1毫升含藥注射筆 1毫升含藥預充填注射器 各100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "111\/12\/07",
    "主成分略述": "Ixekizumab",
    "限制項目": "02輸　入 5E已執行國內臨床試驗 5F免除銜接性試驗",
    "申請商名稱": "台灣禮來股份有限公司",
    "申請商地址": "台北市復興北路３６５號１１樓",
    "主製造廠": [
        {
            "製造廠名稱": "ELI LILLY AND COMPANY",
            "製造廠廠址": "INDIANAPOLIS, INDIANA 46285, U.S.A.",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "Eli Lilly Kinsale Limited",
            "製造廠廠址": "Dunderrow Kinsale, Co. Cork Ireland",
            "製造廠公司地址": "",
            "製造廠國別": "IRELAND",
            "製程": "原料藥製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200081320",
            "成分名稱": "Ixekizumab",
            "含量描述": "",
            "含量": "80.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "blue-pen-big-107-09-06(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001063&Seq=002&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "仿單核定本_Proposed Truth_USPI_TAL-0010-USPI-20210310_v2 - Clean-111-02-17.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001063&Seq=018&Type=9"
        },
        {
            "title": "Taltz_Proposed Truth_USPI_TAL-0009-USPI-20200529_v2 -Clean (仿單)-110-06-23.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001063&Seq=016&Type=9"
        },
        {
            "title": "Taltz nr-AsSpA 使用說明-109-10-29.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001063&Seq=015&Type=9"
        },
        {
            "title": "附件二 AI Carton_Hidden Needle-109-03-02.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001063&Seq=006&Type=8"
        },
        {
            "title": "1056040838-TALTZ-標籤(預充填注射器)-106-12-25.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001063&Seq=004&Type=8"
        },
        {
            "title": "1056040838-TALTZ-標籤(自動注射筆)-106-12-25.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001063&Seq=003&Type=8"
        },
        {
            "title": "1056040838-TALTZ-外盒(預充填注射器)-106-12-25.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001063&Seq=002&Type=8"
        }
    ]
}